EUCTR2022-000294-67-IT进行中（未招募）1 期
A Phase II Study of Adjuvant Nivolumab Switch from Intravenous (IV) to Subcutaneous (SC) Use in Participants with Resected Stage III or Stage IV Melanoma or High Risk Invasive Urothelial Carcinoma Originating in the Bladder -
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Eligible for adjuvant therapy for melanoma or muscle-invasive urothelial carcinoma originating from the bladder
- •Melanoma: resected Stage IIIA/B/C/D or Stage IV (AJCC 8th edition)
- •Bladder: pT3-pT4a or pN+ ineligible or refusal of adjuvant cisplatin chemotherapy OR ypT2-pT4a or ypN+ who received neo-adjuvant cisplatin chemotherapy
- •ECOG performance status 0-1; =18
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 62
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 26
排除标准
- •Ocular or mucosal melanoma
- •Upper tract urothelial carcinoma (ureter, renal pelvis), NMIBC
- •Untreated/unresected CNS or leptomeningeal metastases
- •Prior treatment with immuno-oncology agents
研究者
相似试验
进行中（未招募）
1 期
A Study of Nivolumab IV to Subcutaneous Switch in Adjuvant Melanoma and Bladder CancerStage III A/B/C/D, Stage IV melanoma or Muscle-Invasive Urothelial CarcinomaEUCTR2022-000294-67-DEBristol-Myers Squibb International Corporation88
撤回
2 期
A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder CancerUrothelial CarcinomaMelanomaNCT05496192Bristol-Myers Squibb
进行中（未招募）
1 期
ivolumab administered before surgery in patients with glioblastoma multiformeMedDRA version: 18.0Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Glioblastoma multiformeEUCTR2015-000442-39-ESClinica Universidad de Navarra/Universidad de Navarra30
撤回
不适用
A Phase II Study of Nivolumab in Combination with Radiation Therapy as Definitive Treatment for Patients with Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.KCT0004049Samsung Medical Center26
进行中（未招募）
2 期
Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarkerJPRN-jRCTs031180013Kagamu Hiroshi60